C Allele of the PPARδ+294T>C Polymorphism Confers a Higher Risk of Hypercholesterolemia, but not Obesity and Insulin Resistance: A Systematic Review and Meta-Analysis

Abstract

The relationships of the PPARα Leu162Val and PPARδ+294 T>C polymorphisms with metabolic indexes have been reported to be inconsistent and even contradictory. The meta-analysis was conducted to clarify the relationships between the two variants and the indexes of obesity, insulin resistance, and blood lipids. PubMed, Google Scholar, Embase, and Cochrane Library were searched for eligible studies. Standardized mean difference with 95% confidence interval was calculated to estimate the differences in the metabolic indexes between the genotypes of the Leu162Val and+294 T>C polymorphisms. Heterogeneity among studies was assessed by Cochran’s x2-based Q-statistic test. Publication bias was identified by using Begg’s test. Forty-one studies (44 585 subjects) and 33 studies (23 018 subjects) were identified in the analyses for the Leu162Val and+294 T>C polymorphisms, respectively. C allele carriers of the+294 T>C polymorphism had significantly higher levels of total cholesterol and low-density lipoprotein cholesterol than TT homozygotes in the whole population. Notably, C allele carriers of the+294 T>C polymorphism had significantly higher levels of triglycerides and total cholesterol in East Asians, but lower levels of triglycerides in West Asians than TT homozygotes. Regarding the Leu162Val polymorphism, it was found that Val allele carriers had significantly higher levels of blood glucose than Leu/Leu homozygotes only in European Caucasians. The meta-analysis demonstrates that C allele of the+294 T>C polymorphism in PPARδ gene confers a higher risk of hypercholesterolemia, which may partly explain the relationship between this variant and coronary artery disease.

Key words

PPARα - PPARδ - Leu162Val - 294 T>C - hypercholesterolemia

Publication History

Received: 22 October 2022

Accepted after revision: 23 February 2023

Article published online:
03 April 2023

• References

• 1 Enayati A, Ghojoghnejad M, Roufogalis BD. et al. Impact of phytochemicals on PPAR receptors: Implications for disease treatments. PPAR Res 2022; 4714914
• 2 Pan J, Zhou W, Xu R. et al. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease. Biomed Pharmacother 2022; 151: 113127
• 3 Guixé-Muntet S, Biquard L, Szabo G. et al. Review article: vascular effects of PPARs in the context of NASH. Aliment Pharmacol Ther 2022; 56: 209-223
• 4 Chandra A, Kaur P, Sahu SK. et al. A new insight into the treatment of diabetes by means of pan PPAR agonists. Chem Biol Drug Des 2022; 100: 947-967
• 5 Pyper SR, Viswakarma N, Yu S. et al. PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal 2010; 8: e002
• 6 Tahri-Joutey M, Andreoletti P, Surapureddi S. et al. Mechanisms mediating the regulation of peroxisomal fatty acid beta-oxidation by PPARα. Int J Mol Sci 2021; 22: 8969
• 7 Liu Y, Colby JK, Zuo X. et al. The role of PPAR-δ in metabolism, inflammation, and cancer: many characters of a critical transcription factor. Int J Mol Sci 2018; 19: 3339
• 8 Luquet S, Gaudel C, Holst D. et al. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes. Biochim Biophys Acta 2005; 1740: 313-317
• 9 Skoczynska A, Dobosz T, Poreba R. et al. The dependence of serum interleukin-6 level on PPAR-alpha polymorphism in men with coronary atherosclerosis. Eur J Intern Med 2005; 16: 501-506
• 10 Yilmaz-Aydogan H, Kurnaz O, Kucukhuseyin O. et al. Different effects of PPARA, PPARG and ApoE SNPs on serum lipids in patients with coronary heart disease based on the presence of diabetes. Gene 2013; 523: 20-26
• 11 Nikitin AG, Chistiakov DA, Minushkina LO. et al. Association of the CYBA, PPARGC1A, PPARG3, and PPARD gene variants with coronary artery disease and metabolic risk factors of coronary atherosclerosis in a Russian population. Heart Vessels 2010; 25: 229-236
• 12 Wang LF, Tan M, Chang H. et al. Relationship of peroxisome proliferator-activated receptor-delta+294T/C gene polymorphism with coronary heart disease. Acta Uni Med Anhui 2008; 43: 701-705
• 13 Jguirim-Souissi I, Jelassi A, Hrira Y. et al. +294T/C polymorphism in the PPAR-delta gene is associated with risk of coronary artery disease in normolipidemic Tunisians. Genet Mol Res 2010; 9: 1326-1333
• 14 Robitaille J, Brouillette C, Houde A. et al. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome. J Hum Genet 2004; 49: 482-489
• 15 Shin MJ, Kanaya AM, Krauss RM. Polymorphisms in the peroxisome proliferator activated receptor alpha gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians. Atherosclerosis 2008; 198: 313-319
• 16 Smalinskiene A, Petkeviciene J, Luksiene D. et al. Association between APOE, SCARB1, PPARα polymorphisms and serum lipids in a population of Lithuanian adults. Lipids Health Dis 2013; 12: 120
• 17 Tai ES, Demissie S, Cupples LA. et al. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002; 22: 805-810
• 18 Tanaka T, Ordovas JM, Delgado-Lista J. et al. Peroxisome proliferator-activated receptor alpha polymorphisms and postprandial lipemia in healthy men. J Lipid Res 2007; 48: 1402-1408
• 19 Zhang Y, Lei H, Deng YP. A study on the PPARα gene polymorphisms in diylipidaemia of coronary artery disease subjects. Med J Wuhan Uni 2005; 26: 5-7
• 20 Evans D, Aberle J, Wendt D. et al. A polymorphism, L162V, in the peroxisome proliferator-activated receptor alpha (PPARalpha) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus. J Mol Med (Berl) 2001; 79: 198-204
• 21 Mohamed Youssef S, Mohamed N, Afef S. et al. Interaction effects of the Leu162Val PPAR α and Pro12Ala PPAR γ 2 gene variants with renal function in metabolic syndrome population. PPAR Res 2013; 329862
• 22 Manresa JM, Zamora A, Tomás M. et al. Relationship of classical and non-classical risk factors with genetic variants relevant to coronary heart disease. Eur J Cardiovasc Prev Rehabil 2006; 13: 738-744
• 23 Tai ES, Collins D, Robins SJ. et al. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 2006; 187: 153-160
• 24 Khan QH, Pontefract DE, Iyengar S. et al. Evidence of differing genotypic effects of PPARalpha in women and men. J Med Genet 2004; 41: e79
• 25 Nielsen EM, Hansen L, Echwald SM. et al. Evidence for an association between the Leu162Val polymorphism of the PPARalpha gene and decreased fasting serum triglyceride levels in glucose tolerant subjects. Pharmacogenetics 2003; 13: 417-423
• 26 Ortega-Meléndez AI, Montero-Molina S, Jiménez-Ortega RF. et al. PPARα polymorphisms association with total cholesterol and LDL-C levels in a Mexican population. Eur Rev Med Pharmacol Sci 2022; 26: 2158-2164
• 27 Maciejewska-Skrendo A, Buryta M, Czarny W. et al. The polymorphisms of the peroxisome-proliferator activated receptors’ alfa gene modify the aerobic training induced changes of cholesterol and glucose. J Clin Med 2019; 8: 1043
• 28 Rudkowska I, Garenc C, Couture P. et al. Omega-3 fatty acids regulate gene expression levels differently in subjects carrying the PPARalpha L162V polymorphism. Genes Nutr 2009; 4: 199-205
• 29 Caron-Dorval D, Paquet P, Paradis AM. et al. Effect of the PPAR-Alpha L162V polymorphism on the cardiovascular disease risk factor in response to n-3 polyunsaturated fatty acids. J Nutrigenet Nutrigenomics 2008; 1: 205-212
• 30 Gouni-Berthold I, Giannakidou E, Müller-Wieland D. et al. Association between the PPARalpha L162V polymorphism, plasma lipoprotein levels, and atherosclerotic disease in patients with diabetes mellitus type 2 and in nondiabetic controls. Am Heart J 2004; 147: 1117-1124
• 31 Ren C, Geng FT, Zhang RZ. Relation between Chinese medicine syndrome and PPARD -87C>T gene polymorphism in newly diagnosed type 2 diabetes patients. J Trad Chin Med 2012; 53: 1397-1400
• 32 Yu XJ, Su BL, Wang XM. et al. Relationship between the -87T/C polymorphism in PPARδ gene and metabolism in patients with type 2 diabetes mellitus. Chin J Gerontol 2011; 31: 1144-1146
• 33 Chen S, Tsybouleva N, Ballantyne CM. et al. Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 2004; 14: 61-71
• 34 Wei XL, Yin RX, Miao L. et al. The peroxisome proliferator-activated receptor delta+294T>C polymorphism and alcohol consumption on serum lipid levels. Lipids Health Dis 2011; 10: 242
• 35 Miao L, Yin RX, Wu DF. et al. Peroxisome proliferator-activated receptor delta+294T>C polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations. Lipids Health Dis 2010; 9: 145
• 36 Yılmaz-Aydogan H, Kucukhuseyin O, Kurnaz O. et al. Investigation of polymorphic variants of PPARD and APOE genes in Turkish coronary heart disease patients. DNA Cell Biol 2012; 31: 867-875
• 37 Song JF, Zhu J, Gao QF. et al. Relationship between the PPARD rs2016520 polymorphism and the response to nateglinide treatment. Pract Pharm Clin Remed 2015; 18: 1297-1300
• 38 Song JF, Wang T, Zhu J. et al. PPARD rs2016520 polymorphism affects repaglinide response in Chinese Han patients with type 2 diabetes mellitus. Clin Exp Pharmacol Physiol 2015; 42: 27-32
• 39 Wang T, Song JF, Zhou XY. et al. PPARD rs2016520 (T/C) and NOS1AP rs12742393 (A/C) polymorphisms affect therapeutic efficacy of nateglinide in Chinese patients with type 2 diabetes mellitus. BMC Med Genomics 2021; 14: 267
• 40 Luo CY, Liu CW, Ge L. et al. PPARD+294C overrepresentation in general and long-lived population in China Bama longevity area and unique relationships between PPARD+294T/C polymorphism and serum lipid profiles. Lipids Health Dis 2015; 14: 17
• 41 Vänttinen M, Nuutila P, Kuulasmaa T. et al. Single nucleotide polymorphisms in the peroxisome proliferator-activated receptor delta gene are associated with skeletal muscle glucose uptake. Diabetes 2005; 54: 3587-3591
• 42 Yin RX, Wu DF, Miao L. et al. Interactions of several single nucleotide polymorphisms and high body mass index on serum lipid traits. Biofactors 2013; 39: 315-325
• 43 Vohl MC, Lepage P, Gaudet D. et al. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 2000; 41: 945-952
• 44 Puckey LH, Knight BL. Variation at position 162 of peroxisome proliferator-activated receptor alpha does not influence the effect of fibrates on cholesterol or triacylglycerol concentrations in hyperlipidaemic subjects. Pharmacogenetics 2001; 11: 619-624
• 45 Flavell DM, Jamshidi Y, Hawe E. et al. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation 2002; 105: 1440-1445
• 46 Bossé Y, Pascot A, Dumont M. et al. Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. Genet Med 2002; 4: 311-315
• 47 Eurlings PM, van der Kallen CJ, Geurts JM. et al. Identification of the PPARA locus on chromosome 22q13.3 as a modifier gene in familial combined hyperlipidemia. Mol Genet Metab 2002; 77: 274-281
• 48 Bossé Y, Després JP, Bouchard C. et al. The peroxisome proliferator-activated receptor alpha L162V mutation is associated with reduced adiposity. Obes Res 2003; 11: 809-816
• 49 Paradis AM, Fontaine-Bisson B, Bossé Y. et al. The peroxisome proliferator-activated receptor alpha Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men. Am J Clin Nutr 2005; 81: 523-530
• 50 Volcik KA, Nettleton JA, Ballantyne CM. et al. Peroxisome proliferator-activated receptor [alpha] genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study. Am J Clin Nutr 2008; 87: 1926-1931
• 51 Doney AS, Fischer B, Lee SP. et al. Association of common variation in the PPARA gene with incident myocardial infarction in individuals with type 2 diabetes: a Go-DARTS study. Nucl Recept 2005; 3: 4
• 52 Sparsø T, Hussain MS, Andersen G. et al. Relationships between the functional PPARalpha Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people. Mol Genet Metab 2007; 90: 205-209
• 53 Pishva H, Mahboob SA, Mehdipour P. et al. Association between the FABP2 Ala54Thr, PPARα Leu162/Val, and PPARα intron7 polymorphisms and blood lipids ApoB and ApoCIII in hypertriglyceridemic subjects in Tehran. J Clin Lipidol 2009; 3: 187-194
• 54 Silbernagel G, Stefan N, Hoffmann MM. et al. The L162V polymorphism of the peroxisome proliferator activated receptor alpha gene (PPARA) is not associated with type 2 diabetes, BMI or body fat composition. Exp Clin Endocrinol Diabetes 2009; 117: 113-118
• 55 Neugebauer P, Goldbergová-Pávková M, Kala P. et al. Nuclear receptors gene polymorphisms and risk of restenosis and clinical events following coronary stenting. Vnitr Lek 2009; 55: 1135-1140
• 56 Rudkowska I, Caron-Dorval D, Verreault M. et al. PPARalpha L162V polymorphism alters the potential of n-3 fatty acids to increase lipoprotein lipase activity. Mol Nutr Food Res 2010; 54: 543-550
• 57 Alsaleh A, Frost GS, Griffin BA. et al. PPARγ2 gene Pro12Ala and PPARα gene Leu162Val single nucleotide polymorphisms interact with dietary intake of fat in determination of plasma lipid concentrations. J Nutrigenet Nutrigenomics 2011; 4: 354-366
• 58 Pishva H, Mehdipour P, Eshraghian MR. et al. Effects of eicosapentaenoic acid supplementation on lipid and lipoprotein profile in hypertriglyceridemic subjects with different proliferator-activated receptor alpha genotypes. Int J Prev Med 2014; 5: 333-340
• 59 Lima LO, Almeida S, Hutz MH. et al. PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms and lipid and lipoprotein levels in a Southern Brazilian population. Mol Biol Rep 2013; 40: 1241-1247
• 60 Domenici FA, Brochado MJ, Martinelli Ade L. et al. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients. Gene 2013; 529: 326-331
• 61 Carvalho MD, Alonso DP, Vendrame CM. et al. Lipoprotein lipase and PPAR alpha gene polymorphisms, increased very-low-density lipoprotein levels, and decreased high-density lipoprotein levels as risk markers for the development of visceral leishmaniasis by Leishmania infantum. Mediators Inflamm 2014; 2014: 230129
• 62 Binia A, Vargas-Martínez C, Ancira-Moreno M. et al. Improvement of cardiometabolic markers after fish oil intervention in young Mexican adults and the role of PPARα L162V and PPARγ2 P12A. J Nutr Biochem 2017; 43: 98-106
• 63 Bouchard-Mercier A, Godin G, Lamarche B. et al. Effects of peroxisome proliferator-activated receptors, dietary fat intakes and gene-diet interactions on peak particle diameters of low-density lipoproteins. J Nutrigenet Nutrigenomics 2011; 4: 36-48
• 64 Chia PP, Fan SH, Say YH. Screening of peroxisome proliferator-activated receptors (PPARs) α, γ and α gene polymorphisms for obesity and metabolic syndrome association in the multi-ethnic Malaysian population. Ethn Dis 2015; 25: 383-390
• 65 Skogsberg J, McMahon AD, Karpe F. et al. Peroxisome proliferator activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J Intern Med 2003; 254: 597-604
• 66 Skogsberg J, Kannisto K, Cassel TN. et al. Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 2003; 23: 637-643
• 67 Shin HD, Park BL, Kim LH. et al. Genetic polymorphisms in peroxisome proliferator-activated receptor delta associated with obesity. Diabetes 2004; 53: 847-851
• 68 Gouni-Berthold I, Giannakidou E, Faust M. et al. The peroxisome proliferator-activated receptor delta+294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls. Atherosclerosis 2005; 183: 336-341
• 69 Yan ZC, Shen CY, Zhong J. et al. PPARδ+294T/C gene polymorphism related to plasma lipid, obesity and left ventricular hypertrophy in subjects with metabolic syndrome. Chin J Cardiol 2005; 33: 529-533
• 70 Hu C, Jia W, Fang Q. et al. Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects. Diabet Med 2006; 23: 1307-1312
• 71 Aberle J, Hopfer I, Beil FU. et al. Association of the T+294C polymorphism in PPAR delta with low HDL cholesterol and coronary heart disease risk in women. Int J Med Sci 2006; 3: 108-111
• 72 Grarup N, Albrechtsen A, Ek J. et al. Variation in the peroxisome proliferator-activated receptor delta gene in relation to common metabolic traits in 7,495 middle-aged white people. Diabetologia 2007; 50: 1201-1208
• 73 Hautala AJ, Leon AS, Skinner JS. et al. Peroxisome proliferator-activated receptor-delta polymorphisms are associated with physical performance and plasma lipids: the HERITAGE Family Study. Am J Physiol Heart Circ Physiol 2007; 292: H2498-H2505
• 74 Robitaille J, Gaudet D, Pérusse L. et al. Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta -87T>C polymorphism and dietary fat in French-Canadians. Int J Obes (Lond) 2007; 31: 411-417
• 75 Christopoulos P, Mastorakos G, Gazouli M. et al. Peroxisome proliferator-activated receptor-γ and -δ polymorphisms in women with polycystic ovary syndrome. Ann N Y Acad Sci 2010; 1205: 185-191
• 76 Chiu LL, Chen TW, Hsieh SS. et al. ACE I/D, ACTN3 R577X, PPARD T294C and PPARGC1A Gly482Ser polymorphisms and physical fitness in Taiwanese late adolescent girls. J Physiol Sci 2012; 62: 115-121
• 77 Chehaibi K, Hrira MY, Rouis M. et al. Effect of genetic polymorphism+294T/C in peroxisome proliferator-activated receptor delta on the risk of ischemic stroke in a Tunisian population. J Mol Neurosci 2013; 50: 360-367
• 78 Tang L, Lü Q, Cao H. et al. PPARD rs2016520 polymorphism is associated with metabolic traits in a large population of Chinese adults. Gene 2016; 585: 191-195
• 79 Leońska-Duniec A, Cieszczyk P, Jastrzębski Z. et al. The polymorphisms of the PPARD gene modify post-training body mass and biochemical parameter changes in women. PLoS One 2018; 13: e0202557
• 80 Carrillo-Venzor MA, Erives-Anchondo NR, Moreno-González JG. et al. Pro12Ala PPAR-γ2 and+294T/C PPAR-δ polymorphisms and association with metabolic traits in teenagers from Northern Mexico. Genes (Basel) 2020; 11: 776
• 81 Li S, He C, Nie H. et al. G Allele of the rs1801282 polymorphism in PPARγ gene confers an increased risk of obesity and hypercholesterolemia, while T allele of the rs3856806 polymorphism displays a protective role against dyslipidemia: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2022; 13: 919087
• 82 Song Y, Li S, He C. PPARγ Gene polymorphisms, metabolic disorders, and coronary artery disease. Front Cardiovasc Med 2022; 9: 808929
• 83 Song Y, Raheel TM, Jia A. et al. rs10865710 polymorphism in PPARG promoter is associated with the severity of type 2 diabetes mellitus and coronary artery disease in a Chinese population. Postgrad Med J 2022; 98: 778-787
• 84 Wu Y, Lin X, Hong H. et al. Endothelium-targeted delivery of PPARδ by adeno-associated virus serotype 1 ameliorates vascular injury induced by hindlimb ischemia in obese mice. Biomed Pharmacother 2022; 151: 113172
• 85 hou J, Zhe R, Guo X. et al. The role of PPARδ agosnist GW501516 in rats with gestational diabetes mellitus. Diabetes Metab Syndr Obes 2020; 13: 2307-2316
• 86 Yang H, Zhao H, Ren Z. et al. Overexpression CPT1A reduces lipid accumulation via PPARα/CD36 axis to suppress the cell proliferation in ccRCC. Acta Biochim Biophys Sin (Shanghai) 2022; 54: 220-231
• 87 Papatheodorou I, Makrecka-Kuka M, Kuka J. et al. Pharmacological activation of PPARβ/δ preserves mitochondrial respiratory function in ischemia/reperfusion via stimulation of fatty acid oxidation-linked respiration and PGC-1α/NRF-1 signaling. Front Endocrinol (Lausanne) 2022; 13: 941822
• 88 Park S, Baek IJ, Ryu JH. et al. PPARα-ACOT12 axis is responsible for maintaining cartilage homeostasis through modulating de novo lipogenesis. Nat Commun 2022; 13: 3
• 89 Wu X, Cheng B, Guo X. et al. PPARα/γ signaling pathways are involved in Chlamydia pneumoniae-induced foam cell formation via upregulation of SR-A1 and ACAT1 and downregulation of ABCA1/G1. Microb Pathog 2021; 161: 105284
• 90 Shizu R, Ezaki K, Sato T. et al. PXR suppresses PPARα-dependent HMGCS2 gene transcription by inhibiting the interaction between PPARα and PGC1α. Cells 2021; 10: 3550
• 91 Baghbani-Oskouei A, Gholampourdehaki M. Anthropometric measures and the risk of coronary artery disease. Caspian J Intern Med 2020; 11: 183-190
• 92 Solymanzadeh F, Rokhafroz D, Asadizaker M. et al. Prediction of risk of coronary artery disease based on Framingham Risk Score in association with shift work among nurses. Int J Occup Saf Ergon 2022; 1-17
• 93 Agrawal S, Klarqvist MDR, Emdin C. et al. Selection of 51 predictors from 13,782 candidate multimodal features using machine learning improves coronary artery disease prediction. Patterns (N Y) 2021; 2: 100364
• 94 Yusuf S, Hawken S, Ounpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952
• 95 Fan S, Meng J, Zhang L. et al. CAV1 polymorphisms rs1049334, rs1049337, rs7804372 might be the potential risk in tumorigenicity of urinary cancer: A systematic review and meta-analysis. Pathol Res Pract 2019; 215: 151-158
• 96 Luo B, Yang HW, Long FW. et al. Intratumoral polymorphism of peroxisome proliferator-activated receptor delta-87 T>C in colorectal cancer. Neoplasma 2019; 66: 609-618
• 97 Zhang Y, Gao T, Hu S. et al. The functional SNPs in the 5′ regulatory region of the porcine PPARD gene have significant association with fat deposition traits. PLoS One 2015; 10: e0143734